Aortic Valve Industry Growth, Development and Demand Forecast Report, 2030

NEW YORK - March 15, 2023 - PRLog -- According to the World Health Organization (WHO), rheumatic heart disease (RHD) is a highly prevalent heart disease among people below 25 years of age. This disease claims around 288,348 lives every year, a majority of which are recorded in low- or middle-income countries (LMICs). This disease results in damage to the heart valves by one or multiple bouts of rheumatic fever, which can result in death or life-long disability. Thus, the increasing prevalence of RHD will create a huge requirement for aortic valves in the foreseeable future.

Besides, the surging focus of governments and international organizations on spreading awareness about valve replacement will help the aortic valve market advance at an exceptional CAGR of over 13% in the coming years. The market was valued at $7,568.3 billion in 2019, and it is projected to generate $29,146.9 million revenue by 2030. For example, the Valve for Life initiative of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) aims to increase the accessibility of transcatheter valve procedures in European nations, impart knowledge about valvular diseases, and reduce obstacles for therapy implementation.

Presently, the aortic valve market (https://www.psmarketresearch.com/market-analysis/aortic-v...) is dominated by Anteris Technologies Ltd., Abbott Laboratories, Boston Scientific Corporation, Coroneo Inc., CryoLife Inc., Edwards Lifesciences Corporation, JenaValve Technology Inc., LivaNova PLC, LifeNet Health Inc., Medtronic plc, and Thubrikar Aortic Valve Inc. Nowadays, these companies are actively launching new products and pursuing the approval of regulatory organizations to meet the needs of heart patients. For example, in September 2019, Medtronic plc launched the Evolut PRO+ TAVR system to provide an improved valve sealing performance.

According to P&S Intelligence, the European region is the dominant user of aortic valves due to the presence of well-developed healthcare infrastructure, high prevalence of CVDs, hefty healthcare expenditure, and the existence of a vast geriatric population. Additionally, the emergence of effective heart treatment methods and devices and the massive prevalence of aortic stenosis will facilitate the use of aortic valves in the region. Moreover, the mounting public awareness about valve replacement surgeries will encourage the adoption of this medical product in European countries.

Therefore, the surging incidence of RHD and mounting public awareness about valve replacement procedures will augment the use of aortic valves globally.